PIPELINE
![pipeline pipeline](https://www.tahopharma.com/upload/more_info_b/ALL_more_info_23I25_egQqDamnl1.png)
PRODUCT DEVELOPMENT
Commercial in Japan
TAHO's first approved product - A patient-friendly ODF formulation of a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Currently marketed in Japan.
This immediate release lingual film is designed for easy administration. As an anti-emetic treatment that does not require swallowing. It is an ideal at-home medication for the treatment of chemo therapy-induced nausea side-effect.